Jounce Therapeutics News

JNCEDelisted Stock  USD 1.88  0.00  0.00%   
About 56% of Jounce Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Jounce Therapeutics suggests that many traders are alarmed regarding Jounce Therapeutics' prospects. Jounce Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Jounce Therapeutics. The current market sentiment, together with Jounce Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Jounce Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Jounce Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Jounce daily returns and investor perception about the current price of Jounce Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at bizjournals.com         
Jounce pivots, agrees to 96.5M acquisition by mysterious biotech
bizjournals News
over a year ago at news.google.com         
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
Google News at Macroaxis
over a year ago at news.google.com         
Jounce Therapeutics Inc Down 0.63 percent in Premarket Trading - InvestorsObserver
Google News at Macroaxis
over a year ago at news.google.com         
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
Google News at Macroaxis
over a year ago at news.google.com         
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
Google News at Macroaxis
over a year ago at benzinga.com         
Jounce Therapeutics Says JTX-8064Pimivalimab Shows Deep, Durable Responses In Pretreated Ovarian Can...
benzinga news
over a year ago at kalkinemedia.com         
Tang Capital Management - Concentra Delivered Letter To Jounce Therapeutics Extending Expiration Dat...
news
over a year ago at 247wallst.com         
Tang Capital Partners Now Owns 10.2 percent of Jounce Therapeutics
news
over a year ago at zacks.com         
Jounce Up 41 percent on Buyout Offer From Concentra Biosciences
zacks News
over a year ago at hawaiinewsnow.com         
SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates JNCE, ADAP, TCRR
news
over a year ago at finance.yahoo.com         
Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-80...
Yahoo News
over a year ago at investing.com         
Jounce Therapeutics Reports Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064...
Investing News at Macroaxis
over a year ago at kalkinemedia.com         
Jounce Therapeutics Announces Results From Pre-Planned Data Review Of Innate Phase 2 Trial Of Jtx-80...
news
over a year ago at kalkinemedia.com         
Jounce Therapeutics Confirms Receipt Of Unsolicited Proposal From Concentra Biosciences
news
over a year ago at marketwatch.com         
Jounce Therapeutics Jumps Premarket on Buyout Bid JNCE
marketwatch News
Far too much social signal, news, headlines, and media speculation about Jounce Therapeutics that are available to investors today. That information is available publicly through Jounce media outlets and privately through word of mouth or via Jounce internal channels. However, regardless of the origin, that massive amount of Jounce data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jounce Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jounce Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jounce Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jounce Therapeutics alpha.

Jounce Therapeutics Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
Stocks to Watch eBay, Etsy, Jounce Therapeutics, Dutch Bros, Cheesecake Factory
02/22/2023
2
Jounce Therapeutics Inc expected to post a loss of9cents a share - Earnings Preview
02/24/2023
3
Why Is Boxed Stock Down 41 percent Today
03/15/2023
4
JNCE STOCK ALERT Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders
03/27/2023
5
Jounce Up 21 percent on Accepting Concentras Buyout Offer
03/28/2023
6
Millennium Partners, L.P. UK Regulatory Announcement Form 8.3 ... - ACROFAN USA
03/30/2023
7
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
04/03/2023
8
Jounce Therapeutics, Inc. Short Interest Down 11.4 percent in April
05/01/2023
9
Jounce Therapeutics Announces Closing of Tender Offer
05/04/2023
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
Note that the Jounce Therapeutics information on this page should be used as a complementary analysis to other Jounce Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Other Consideration for investing in Jounce Stock

If you are still planning to invest in Jounce Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Jounce Therapeutics' history and understand the potential risks before investing.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Equity Valuation
Check real value of public entities based on technical and fundamental data